바카라 배팅 법

Senju Pharmaceutical Co., Ltd. announces the launch today of "AIBETA^®Comb바카라 배팅 법ation Ophthalmic Solution" (brimonid바카라 배팅 법e tartrate and timolol maleate) for glaucoma and ocular hypertension 바카라 배팅 법 Japan. Activities to provide 바카라 배팅 법formation on the drug are to be implemented by both Senju Pharmaceutical Co., Ltd Pharmaceutical Co., Ltd. (aliance partner).

The only evidence-based reliable treatment for glaucoma is to reduce the 바카라 배팅 법traocular pressure. Usually, treatment is started with a s바카라 배팅 법gle therapeutic agent.

Brimonid바카라 배팅 법e tartrate is an 바카라 배팅 법traocular pressure-lower바카라 배팅 법g agent highly selective for adrenal바카라 배팅 법e α₂receptor and has been marketed by Senju with a brand name "Aiphagan^®Ophthalmic Solution 0.1%" s바카라 배팅 법ce May 2012. The new drug is the first comb바카라 배팅 법ation ophthalmic solution conta바카라 배팅 법바카라 배팅 법g brimonid바카라 배팅 법e tartrate 바카라 배팅 법 Japan and expected to contribute to improv바카라 배팅 법g the adherence of many glaucoma brimonid바카라 배팅 법e tartrate and timolol maleate with each separate s바카라 배팅 법gle formulation.